{
    "organizations": [],
    "uuid": "8fc6b482f04defbd6182a16e9291adcd70c4d562",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novocure-reports-qtrly-loss-per-sh/brief-novocure-reports-qtrly-loss-per-share-0-23-idUSFWN1S30JA",
    "ord_in_thread": 0,
    "title": "Novocure Reports Qtrly Loss Per Share $0.23",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Novocure Ltd:\n* NOVOCURE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE\n* 2,009 ACTIVE PATIENTS AT MARCH 31, 2018, AN INCREASE OF 59 PERCENT VERSUS MARCH 31, 2017\n* DELIVERED QUARTERLY NET REVENUES OF $52.1 MILLION, REPRESENTING 49 PERCENT GROWTH VERSUS Q1 2017\n* QTRLY LOSS PER SHARE $0.23 * Q1 EARNINGS PER SHARE VIEW $-0.13, REVENUE VIEW $56.6 MILLION â€” THOMSON REUTERS I/B/E/S Source text for Eikon:\n ",
    "published": "2018-04-26T18:25:00.000+03:00",
    "crawled": "2018-04-27T17:12:22.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "novocure",
        "ltd",
        "novocure",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "company",
        "update",
        "active",
        "patient",
        "march",
        "increase",
        "percent",
        "versus",
        "march",
        "delivered",
        "quarterly",
        "net",
        "revenue",
        "million",
        "representing",
        "percent",
        "growth",
        "versus",
        "q1",
        "qtrly",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon"
    ]
}